{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:40:00Z","timestamp":1763037600591,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":118,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.riam.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T02:50:01Z","timestamp":1620787801000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones f\u00fangicas invasoras en pacientes oncohematol\u00f3gicos"],"prefix":"10.1016","volume":"38","author":[{"given":"Carolina","family":"Garc\u00eda-Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2021.03.001_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00358-18","article-title":"the FILPOP2 Project from GEMICOMED (SEIMC) and REIPI. Molecular identification and susceptibility testing of molds isolated in a prospective surveillance of triazole resistance in Spain (FILPOP2 Study)","volume":"62","author":"Alastruey-Izquierdo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2021.03.001_bib0270","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/jac\/dks189","article-title":"Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: Real-life data from a single-centre institutional retrospective observational study","volume":"67","author":"Auberger","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2021.03.001_bib0275","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/jac\/dkw199","article-title":"A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis","volume":"71","author":"Biehl","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.riam.2021.03.001_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12569","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2021.03.001_bib0285","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2021.03.001_bib0290","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0295","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2021.03.001_bib0300","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/myc.12318","article-title":"Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: A single-centre study with focus on emerging pathogens","volume":"58","author":"Corzo-Le\u00f3n","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2021.03.001_bib0305","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10428194.2018.1485913","article-title":"Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib","volume":"60","author":"Cummins","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.riam.2021.03.001_bib0310","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic approach: Implications for optimal dosing","volume":"69","author":"Dolton","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.riam.2021.03.001_bib0315","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2021.03.001_bib0320","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0325","article-title":"Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain","author":"Escribano","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2021.03.001_bib0330","doi-asserted-by":"crossref","first-page":"e2018063","DOI":"10.4084\/mjhid.2018.063","article-title":"Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs","volume":"10","author":"Facchinelli","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0335","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0340","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.riam.2021.03.001_bib0345","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/03007995.2018.1502659","article-title":"Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis","volume":"34","author":"Herbrecht","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.riam.2021.03.001_bib0350","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.riam.2021.03.001_bib0355","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0360","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1111\/tid.12981","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study","volume":"20","author":"Kuster","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0365","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0370","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: Systematic review and meta-analysis","volume":"9","author":"Lanini","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.riam.2021.03.001_bib0375","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"French Mycosis Study Group. Prospective pilot study of high-dose (10mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2021.03.001_bib0380","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: A 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2021.03.001_bib0385","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","article-title":"Azole antifungals and new targeted therapies for hematological malignancy","volume":"32","author":"Lindsay","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0390","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.medcli.2019.07.026","article-title":"Riesgo de infecci\u00f3n asociada a nuevas terapias para el tratamiento de los s\u00edndromes linfoproliferativos","volume":"154","author":"Los-Arcos","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.riam.2021.03.001_bib0395","doi-asserted-by":"crossref","first-page":"100635","DOI":"10.1016\/j.blre.2019.100635","article-title":"Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections","volume":"40","author":"Maffei","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.riam.2021.03.001_bib0525","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17145","article-title":"for Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM). Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study","volume":"193","author":"Marchesini","year":"2021","journal-title":"Br J Haematol."},{"key":"10.1016\/j.riam.2021.03.001_bib0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0410","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"European Conference on Infections in Leukemia (ECIL). Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"10.1016\/j.riam.2021.03.001_bib0415","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2021.03.001_bib0420","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb04825.x","article-title":"Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-centre experience of 133 episodes in 116 patients","volume":"86","author":"Mills","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.riam.2021.03.001_bib0425","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archinte.1995.00430100129015","article-title":"Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data","volume":"155","author":"Ng","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.riam.2021.03.001_bib0430","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/cis773","article-title":"SEIFEM Group. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: Results from the SEIFEM 2010-B registry","volume":"55","author":"Pagano","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0435","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jinf.2011.12.015","article-title":"Breakthrough invasive mould infections in patients treated with caspofungin","volume":"64","author":"Pang","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.riam.2021.03.001_bib0440","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.riam.2021.03.001_bib0445","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/cid\/ciy406","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.riam.2021.03.001_bib0450","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl B","key":"10.1016\/j.riam.2021.03.001_bib0455","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/28.suppl_B.73","article-title":"Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients","volume":"28","author":"Ringd\u00e9n","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2021.03.001_bib0460","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: Guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"Skiada","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.riam.2021.03.001_bib0465","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study: A randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2021.03.001_bib0470","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.riam.2021.03.001_bib0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2021.03.001_bib0480","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2021.03.001_bib0485","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JCM.00502-15","article-title":"High-level pan-azole-resistant aspergillosis","volume":"53","author":"Van Ingen","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.riam.2021.03.001_bib0490","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0495","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2021.03.001_bib0500","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2021.03.001_bib0505","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2021.03.001_bib0510","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2021.03.001_bib0515","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.riam.2021.03.001_bib0520","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12281-019-00343-9","article-title":"Fungal infections with ibrutinib and other small-molecule kinase inhibitors","volume":"13","author":"Zarakas","year":"2019","journal-title":"Curr Fungal Infect Rep"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:07:43Z","timestamp":1761106063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140621000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1130140621000231"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2021.03.001","relation":{},"ISSN":["1130-1406"],"issn-type":[{"type":"print","value":"1130-1406"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones f\u00fangicas invasoras en pacientes oncohematol\u00f3gicos","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda.","name":"copyright","label":"Copyright"}]}}